• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by vTv Therapeutics Inc.

    8/23/22 3:10:33 PM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTVT alert in real time by email
    SC 13G 1 d326871dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

    vTv Therapeutics Inc.

    (Name of Issuer)

    Class A Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    918385105

    (CUSIP Number)

    August 16, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d - 1(b)

    ☒ Rule 13d - 1(c)

    ☐ Rule 13d - 1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 918385105    SCHEDULE 13G   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Medpace Investors, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      1,242,980

       6  

      SHARED VOTING POWER

     

      4,154,549

       7  

      SOLE DISPOSITIVE POWER

     

      1,242,980

       8  

      SHARED DISPOSITIVE POWER

     

      4,154,549

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      5,397,529

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.16%

    12  

      TYPE OF REPORTING PERSON

     

      OO


    CUSIP No. 918385105    SCHEDULE 13G   

     

      1    

      NAMES OF REPORTING PERSONS

     

      August J. Troendle

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      5,397,529

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      5,397,529

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      5,397,529

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      5.16%

    12  

      TYPE OF REPORTING PERSON

     

      OO


    SCHEDULE 13G

     

    Item 1(a).

    Name of Issuer: vTv Therapeutics Inc. (“Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    3980 Premier Drive, Suite 310

    High Point, NC 27265

     

    Item 2(a).

    Name of Persons Filing: The names of the persons filing this statement on Schedule 13G are:

     

      •  

    Medpace Investors, LLC (“MPI”)

     

      •  

    August J. Troendle

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    5375 Medpace Way

    Cincinnati, Ohio 45227

     

    Item 2(c).

    Citizenship: MPI is a limited liability company organized under the laws of the State of Delaware. Mr. Troendle is a natural person and citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities: Class A Common Stock, par value $0.01 per share (“Common Stock”).

     

    Item 2(e).

    CUSIP Number: 918385105

     

    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b) or Rule 13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Act;
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)    ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
    (i)    ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
    (j)    ☐    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
    (k)    ☐    Group, in accordance with Rule 13d-1(b)(1)(ii)(K).
    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:                    


    Item 4.

    Ownership:

    The information requested hereinafter is set forth in items 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentage of MPI is based on a total of 104,577,460 shares of Common Stock outstanding, which consists of (i) 66,942,777 shares of Common Stock outstanding, (ii) 23,093,860 shares of Common Stock that are issuable in exchange for the 23,093,860 shares of Class B Common Stock and corresponding nonvoting common units outstanding, (iii) 10,386,274 shares issued in connection with the common stock purchase agreement with the Issuer and G42 Investments AI Holding RSC Ltd, and (iv) the 4,154,549 shares of Common Stock issued to CinPax, LLC (“CinPax”) as reported on the Current Report on Form 8-K for the Issuer filed on July 25, 2022.

    CinPax directly holds 4,154,549 shares of Common Stock. MPI indirectly owns approximately 70% of the outstanding common equity of CinPax and, as such, MPI is deemed to have beneficial ownership of the Common Stock held by CinPax.

    August J. Troendle owns a majority of the interests of MPI and may be deemed to have shared voting and investment powers over the shares held and beneficially owned by MPI. Mr. Troendle disclaims beneficial ownership of the shares held or beneficially owned by MPI except to the extent of any pecuniary interest therein.

     

    Item 5.

    Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person: Not Applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person: Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group: Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group: Not Applicable.

     

    Item 10.

    Certifications:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:  

    August 23, 2022

        MEDPACE INVESTORS, LLC
          By:  

    /s/ Stephen P. Ewald

          Name:  

    Stephen P. Ewald, Esq.

          Title:  

    Vice President and Chief Legal Officer

    Date:  

    August 23, 2022

        AUGUST J. TROENDLE
         

    /s/ August J. Troendle

          August J. Troendle


    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of vTv Therapeutics Inc., dated as of August 23, 2022, is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provision of Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended.

     

    Date:  

    August 23, 2022

        MEDPACE INVESTORS, LLC
          By:  

    /s/ Stephen P. Ewald

          Name:  

    Stephen P. Ewald, Esq.

          Title:  

    Vice President and Chief Legal Officer

    Date:  

    August 23, 2022

        AUGUST J. TROENDLE
         

    /s/ August J. Troendle

          August J. Troendle
    Get the next $VTVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTVT

    DatePrice TargetRatingAnalyst
    2/18/2022$5.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $VTVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by vTv Therapeutics Inc.

      SC 13G - vTv Therapeutics Inc. (0001641489) (Subject)

      11/12/24 10:40:28 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by vTv Therapeutics Inc. (Amendment)

      SC 13D/A - vTv Therapeutics Inc. (0001641489) (Subject)

      3/22/24 4:57:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by vTv Therapeutics Inc.

      SC 13D - vTv Therapeutics Inc. (0001641489) (Subject)

      3/5/24 7:52:29 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

      Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate de

      3/20/25 5:35:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

      Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on the cadisegliatin clinical program, which includes

      3/17/25 8:30:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

      WESTON, Fla., Dec. 9, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, received in mid-2024 and early 2023, respectively.

      12/9/24 7:33:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    SEC Filings

    See more
    • SEC Form 144 filed by vTv Therapeutics Inc.

      144 - vTv Therapeutics Inc. (0001641489) (Subject)

      5/1/25 4:28:23 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by vTv Therapeutics Inc.

      DEF 14A - vTv Therapeutics Inc. (0001641489) (Filer)

      4/25/25 4:20:08 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - vTv Therapeutics Inc. (0001641489) (Filer)

      3/31/25 4:30:12 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Pres, CEO and Exec Chairperson Sekhri Paul J bought $83,812 worth of shares (5,000 units at $16.76) (SEC Form 4)

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      11/19/24 4:31:06 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on vTv Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of vTv Therapeutics with a rating of Overweight and set a new price target of $5.00

      2/18/22 6:42:27 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Leadership Updates

    Live Leadership Updates

    See more
    • vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

      Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate de

      3/20/25 5:35:31 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

      HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. "Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on a consulting basis for several months, is now leading our work on the cadisegliatin Phase 3 program with the goal of initiating studies as soon as possible," said Paul Sekhri, Chief Executive Offi

      11/9/23 4:30:00 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

      HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. "I am pleased to welcome Dr. Strack to the vTv team," said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. "He brings extensive drug development and clinical expertise, as well as a wealth of knowledge in endocrine, metabolic, and cardiovascular diseases. We believe his expertise will be invaluable as

      11/2/23 8:00:54 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Financials

    Live finance-specific insights

    See more
    • vTv Therapeutics Announces Investment by CinRx Pharma

      HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ("CinPax"), a subsidiary of CinRx Pharma, LLC ("CinRx"). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA ap

      7/25/22 7:00:00 AM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VTVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Akkaraju Srinivas

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      4/24/25 4:40:29 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Pres, CEO and Exec Chairperson Sekhri Paul J

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      3/7/25 4:20:26 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Samsara Biocapital Gp, Llc disposed of 58,836 shares (SEC Form 4)

      4 - vTv Therapeutics Inc. (0001641489) (Issuer)

      12/6/24 4:15:18 PM ET
      $VTVT
      Biotechnology: Pharmaceutical Preparations
      Health Care